Company / R&D per Share
IOVANCE BIOTHERAPEUTICS, INC. R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$0.98
FY2025
5-year range
$0.98 / $1850.95
FY2021-FY2025
Trend
-8.8%
vs FY2024
Sector context
#147 of 208
Health Care
What the data says
At $0.98, IOVANCE BIOTHERAPEUTICS, INC.'s r&d per share ranks #147 of 208 in the Health Care sector. R&D per Share has declined for 3 consecutive years, from $1850.95 in FY2022 to $0.98 in FY2025.
Based on SEC 10-K filings.
0.98 in FY2025 with a 5-year CAGR of -76.8%.
Declined from $1.77 to $0.98 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -91.9%
- 5-Year CAGR
- -76.8%
- 10-Year CAGR
- -
Sector benchmark
#147 of 208 in Health CareTop 71% of 208This company $0.98 Sector average $12.19
▼
-91.9% below sector average
Key checks
Key Insights
- IOVANCE BIOTHERAPEUTICS, INC.'s r&d per share has declined for 3 consecutive years.
- In FY2025, r&d per share decreased 8.8% year-over-year.
- Ranks #147 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.05 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.98 | -8.8% |
| FY2024 | $1.08 | -39.2% |
| FY2023 | $1.77 | -99.9% |
| FY2022 | $1850.95 | +9.6% |
| FY2021 | $1688.58 | +15.8% |
| FY2020 | $1458.61 | +9.2% |
| FY2019 | $1335.28 | +97763.8% |
| FY2018 | $1.36 | +18.6% |
| FY2017 | $1.15 | +1351.1% |
| FY2016 | $0.08 | +24.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026